Hepatitis por finasterida

Guzmán, M. Martínez de; Martínez-Crespo, Juan José

doi:10.1016/s1130-6343(06)74011-9

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No severe hepatotoxicity or clinical liver injury has been reported. However, some publications report mild transient serum aminotransferase elevations occurring during finasteride therapy [69]. Digoxigenin is a steroid that when attached to sugars forms glycosides.…”

Section: Discussionmentioning

confidence: 99%

ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish

Cornet

Calzolari

Minana-Prieto

et al. 2017

IJMS

View full text Add to dashboard Cite

Toxicity is one of the major attrition causes during the drug development process. In that line, cardio-, neuro-, and hepatotoxicities are among the main reasons behind the retirement of drugs in clinical phases and post market withdrawal. Zebrafish exploitation in high-throughput drug screening is becoming an important tool to assess the toxicity and efficacy of novel drugs. This animal model has, from early developmental stages, fully functional organs from a physiological point of view. Thus, drug-induced organ-toxicity can be detected in larval stages, allowing a high predictive power on possible human drug-induced liabilities. Hence, zebrafish can bridge the gap between preclinical in vitro safety assays and rodent models in a fast and cost-effective manner. ZeGlobalTox is an innovative assay that sequentially integrates in vivo cardio-, neuro-, and hepatotoxicity assessment in the same animal, thus impacting strongly in the 3Rs principles. It Reduces, by up to a third, the number of animals required to assess toxicity in those organs. It Refines the drug toxicity evaluation through novel physiological parameters. Finally, it might allow the Replacement of classical species, such as rodents and larger mammals, thanks to its high predictivity (Specificity: 89%, Sensitivity: 68% and Accuracy: 78%).

show abstract

Section: Discussionmentioning

confidence: 99%

ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish

Cornet

Calzolari

Minana-Prieto

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Existe escasa literatura respecto a la hepatotoxicidad asociada al uso de dichos fármacos, encontrándose 2 reportes de casos de elevación de transaminasas sin clínica significativa tras el uso de finasteride por un cuadro de alopecia, los valores de transaminasas se normalizaron tras la suspensión del medicamento (8) . A pesar de que la dutasterida se metaboliza en el hígado por la isoenzima CYP3A4, sólo se han reportado elevaciones transitorias de transaminasas, que rara vez requirieron modificación de la dosis.…”

Section: Previo Al Tratamientounclassified

Hepatotoxicidad por tamsulosina / dutasterida: reporte de un caso probable

Yance,

Montes

2023

Rev Gastroenterol Peru

View full text Add to dashboard Cite

La tamsulosina y dutasterida son medicamentos ampliamente usados como tratamiento de la hipertrofia benigna de próstata. teniendo un buen perfil de seguridad. Existen escasos reportes de injuria hepática asociado al uso de tamsulosina; sin embargo, no hay reportes de toxicidad hepática por el uso de dutasterida y del uso combinado de tamsulosina/dutasterida. Se presenta el caso de un varón de 64 años quien desarrolla injuria hepática tras el uso combinado de tamsulosina/dutasterida, desarrollando un patrón de daño hepatocelular y clínica de hepatitis aguda. Se realizo descarte de patología hepática viral, autoinmune y enfermedades metabólicas de depósito, así como de patología biliar mediante ecografía abdominal y colangioresonancia. En la evaluación de causalidad, presentó CIOMS-RUCAM: 6 puntos (probable) y Naranjo: 4 puntos (posible). El paciente presentó respuesta clínica y laboratorial luego de suspender el medicamento.

show abstract